Skip to main content


ONC8011 : Cancer Drugs and Technologies: Product Pathway, Provider & Patient (E-learning) (Inactive)

  • Inactive for Year: 2019/20
  • Module Leader(s): Mr Steve Williamson
  • Lecturer: Dr Charles Kelly
  • Owning School: FMS Graduate School
  • Teaching Location: Off Campus
Semester 2 Credit Value: 20
ECTS Credits: 10.0


This module looks at how new cancer medicines are developed, marketed and introduced into clinical practice. The module includes practical examination of how healthcare providers assess the value and affordability of new cancer medicines. The wider context of the impact new concepts in personalised health care and new medicine technologies will be evaluated.

Outline Of Syllabus

•Product Development -Challenges, Barriers and Benefits.
•Phase I/II/III/IV trials are they still relevant?
•Biomarkers, Companion Diagnostics and personalised medicine
•New technologies
•How real decisions are made
•Cancer Drug Fund and the UK approach to commissioning new cancer medicines
•HTA Applications Exercise: Formative Assessment (topic 7)
•Value in Health Care – what is it and how is it measured?
•Affordability, what next for cancer medicines?
•Marketing and Promotion – does it make a difference to prescribers
•Models of Joint Working between industry and healthcare systems.

Teaching Methods

Teaching Activities
Category Activity Number Length Student Hours Comment
Guided Independent StudyAssessment preparation and completion310:0030:00Independent assessment preparation
Guided Independent StudyDirected research and reading125:0060:00Online content
Guided Independent StudySkills practice12:002:00Skills practice using personal capture software
Guided Independent StudyReflective learning activity123:0036:00eJournal
Guided Independent StudyIndependent study123:0036:00Supplemental reading
Guided Independent StudyOnline Discussion123:0036:00Via discussion board
Teaching Rationale And Relationship

Through a series of online tutorials and weekly activities as well as private study (including directed reading) students will gain a detailed knowledge of understanding of how cancer medicines reach patients in the ‘real world’ and gain and insight to the challenges faced by health systems and clinical and financial decision making. Students are encouraged to participate in online collaborative discussions via the discussion boards so they can help debate current practices and the reflective journal will help to consolidate their understanding of the curriculum.

Assessment Methods

The format of resits will be determined by the Board of Examiners

Description Length Semester When Set Percentage Comment
Oral Presentation152M40Recorded powerpoint presentation. Max 10 slides, max 15 minute presentation.
Other Assessment
Description Semester When Set Percentage Comment
Essay2M50Two short essay questions (1000 words each).
Portfolio2M10Participation in collaborative e-learning activities throughout the module.
Assessment Rationale And Relationship

This assessment strategy is designed to allow the students' to demonstrate a depth of knowledge in a focused topic of a non-prescriptive aspect of cancer management. It allows assessment of students ability to critically analyse and present to an audience of peers a focused critiqued piece of work.

The short essay questions are designed to assess the students' knowledge and understanding across the breadth of all topics covered in the module.

A participation grade is included to encourage and reward the student's engagement with the
collaborative activities.

Should a student fail the participation assessment and have to undertake a re-sit they will have to
complete a different form of assessment. The student will be asked to look at 2 participation
activities as identified by the module leader/team and submit a 500 word written summary (approx. 250 words per activity).

Reading Lists